Specifications of Lenalidomide丨191732-72-6
|
|
|
|
Off-white to light yellow powder |
|
|
99.5% min |
|
|
4% max |
|
|
0.5% max |
|
|
0.1% max |
|
|
10 ppm max |
|
|
10 ppm max |
Manufacturing Information of Lenalidomide丨191732-72-6
|
|
|
|
4MT/month |
|
|
Production since 2015 |
|
Lenalidmide丨191732-72-6 is a synthetic derivative f thalidmide, belnging t the class f immunmdulatry drugs (IMiDs). It is used primarily in the treatment f hematlgical cancers and autimmune diseases due t its ability t mdify the immune system and target cancer cells.
Applicatins f Lenalidmide丨191732-72-6
1. Treatment f Hematlgical Cancers
It is als used t treat myeldysplastic syndrmes with del(5q) chrmsmal abnrmalities, imprving the red bld cell cunt and quality f life fr patients.
2. Autimmune Diseases
3. Clinical Research and Trials
Benefits f Lenalidmide丨191732-72-6
1. Effective Anti-Cancer Prperties
● Lenalidmide丨191732-72-6 wrks by mdulating the immune system, enhancing the bdy's ability t attack cancer cells, particularly in cnditins like multiple myelma and mantle cell lymphma.
2. Imprved Quality f Life in Cancer Patients
3. Immune System Mdulatin
● Lenalidmide enhances immune respnses by increasing T-cell functin and prducing cytkines, which play a critical rle in the fight against cancer and autimmune diseases.
4. ral Administratin and Cnvenience
● It is administered rally, prviding cnvenience ver intravenus therapies, which is an advantage fr lng-term treatment regimens.
5. Brad Applicatins in Cancer and Autimmune Disrders
Lenalidmide丨191732-72-6 is an imprtant immunmdulatry drug with effective applicatins in treating hematlgical cancers like multiple myelma and myeldysplastic syndrmes. It als shws prmise in autimmune disease management. Its ability t mdulate the immune system, target cancer cells, and imprve patient utcmes makes it a vital therapeutic tl in mdern medicine.
Δημοφιλείς Ετικέτες: lenalidomide丨cas 191732-72-6, China lenalidomide丨cas 191732-72-6 manufacturers, suppliers, factory
